US 9527841
Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
granted A61PA61P25/18A61P25/28
Quick answer
US patent 9527841 (Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors) held by Takeda Pharmaceutical Company Limited expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Dec 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61P, A61P25/18, A61P25/28, A61P43/00